Pulmonary Cryptococcosis

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 5, 2015, Pages 681-691

  Chang, C C ^a,b,c   Sorrell, T C ^d,e   Chen, S C A ^d,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d University of Sydney   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

Author keywords

C. gattii; C. neoformans; cryptococcomas; invasive fungal disease; pulmonary cryptococcosis

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; FUNGUS ANTIGEN; METHAMPHETAMINE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CRYPTOCOCCAL MENINGOENCEPHALITIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; FILOBASIDIELLA; FUNGUS CULTURE; GENUS; GRAFT RECIPIENT; HISTOPATHOLOGY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION RISK; LABORATORY DIAGNOSIS; LATENT PERIOD; LUNG BIOPSY; MANAGED CARE; MENINGOENCEPHALITIS; MOLECULAR DIAGNOSIS; MOLECULAR ECOLOGY; MOLECULAR TYPING; OPEN LUNG BIOPSY; ORGAN DONOR; ORGAN TRANSPLANTATION; PATHOGENESIS; PREGNANCY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYSTEM; RISK ASSESSMENT; RISK FACTOR; TAXONOMY; THORAX RADIOGRAPHY; TISSUE SECTION; CRYPTOCOCCOSIS; DIAGNOSTIC ERROR; DISEASE MANAGEMENT; LUNG; LUNG DISEASES, FUNGAL; PATHOLOGY; PRACTICE GUIDELINE;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DIAGNOSTIC ERRORS; DISEASE MANAGEMENT; HUMANS; LUNG; LUNG DISEASES, FUNGAL; PRACTICE GUIDELINES AS TOPIC; RADIOGRAPHY, THORACIC; RISK FACTORS;

EID: 84942240708     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1562895     Document Type: Article

References (103)

1. Park B. J., Wannemuehler K. A., Marston B. J., Govender N., Pappas P. G., Chiller T. M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS: 2009; 23 4 525 530
2. Brown G. D., Denning D. W., Gow N. A., Levitz S. M., Netea M. G., White T. C. Hidden killers: human fungal infections. Sci Transl Med: 2012; 4 165 165rv13
3. Chayakulkeeree M., Perfect J. R. Cryptococcosis. Infect Dis Clin North Am: 2006; 20 3 507 544, v-vi
4. Kwon-Chung K. J., Boekhout T., Wickes B. L., Fell J. W. Systematics of the genus Cryptococcus and its type species C. neoformans. In: Heitman J., Kozel T. R., Kwon-Chung K. J., Perfect J. R., Casadevall A., eds. Cryptococcus-From Human Pathogen to Model Yeast. Washington, DC ASM Press: 2011; 3 15
5. Braun U. The impacts of the discontinuation of dual nomenclature of pleomorphic fungi: the trivial facts, problems, and strategies. IMA Fungus: 2012; 3 1 81 86
6. Hawksworth D. L. Managing and coping with names of pleomorphic fungi in a period of transition. IMA Fungus: 2012; 3 1 15 24
7. De Hoog G. S., Chaturvedi V., Denning D. W., et al. ISHAM Working Group on Nomenclature of Medical Fungi. Name changes in medically important fungi and their implications for clinical practice. J Clin Microbiol: 2015; 53 4 1056 1062
8. Kwon-Chung K. J., Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res: 2006; 6 4 574 587
9. Meyer W., Aanensen D. M., Boekhout T., et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol: 2009; 47 6 561 570
10. Idnurm A., Bahn Y. S., Nielsen K., Lin X., Fraser J. A., Heitman J. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat Rev Microbiol: 2005; 3 10 753 764
11. D'Souza C. A., Kronstad J. W., Taylor G., et al. Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. MBio: 2011; 2 1 e00342 e10
12. Kidd S. E., Hagen F., Tscharke R. L., et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A: 2004; 101 49 17258 17263
13. Lin X., Litvintseva A. P., Nielsen K., et al. alpha AD alpha hybrids of Cryptococcus neoformans: evidence of same-sex mating in nature and hybrid fitness. PLoS Genet: 2007; 3 10 1975 1990
14. Bovers M., Hagen F., Kuramae E. E., et al. AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis: 2008; 14 7 1105 1108
15. Chen S. C., Meyer W., Sorrell T. C. Cryptococcus gattii infections. Clin Microbiol Rev: 2014; 27 4 980 1024
16. Litvintseva A. P., Carbone I., Rossouw J., Thakur R., Govender N. P., Mitchell T. G. Evidence that the human pathogenic fungus Cryptococcus neoformans var. grubii may have evolved in Africa. PLoS ONE: 2011; 6 5 e19688
17. Swinne D., Deppner M., Laroche R., Floch J. J., Kadende P. Isolation of Cryptococcus neoformans from houses of AIDS-associated cryptococcosis patients in Bujumbura (Burundi). AIDS: 1989; 3 6 389 390
18. Harris J., Lockhart S., Chiller T. Cryptococcus gattii: where do we go from here? Med Mycol: 2012; 50 2 113 129
19. Kwon-Chung K. J., Bennett J. E. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol: 1984; 120 1 123 130
20. Galanis E., Macdougall L., Kidd S., Morshed M.; British Columbia Cryptococcus gattii Working Group. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis: 2010; 16 2 251 257 [erratum in: Emerg Infect Dis. 2010 Apr;16(4):750]
21. Marr K. A. Cryptococcus gattii: the tip of the iceberg. Clin Infect Dis: 2011; 53 12 1196 1198
22. Engelthaler D. M., Hicks N. D., Gillece J. D., et al. Cryptococcus gattii in North American Pacific Northwest: whole-population genome analysis provides insights into species evolution and dispersal. MBio: 2014; 5 4 e01464 e14
23. Harris J. R., Lockhart S. R., Sondermeyer G., et al. Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg Infect Dis: 2013; 19 10 1620 1626
24. Hagen F., Ceresini P. C., Polacheck I., et al. Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest. PLoS ONE: 2013; 8 8 e71148
25. Singer L. M., Meyer W., Firacative C., Thompson G. R. III, Samitz E., Sykes J. E. Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America. J Clin Microbiol: 2014; 52 6 2061 2070
26. Sun H. Y., Wagener M. M., Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis: 2009; 48 11 1566 1576
27. Singh N., Alexander B. D., Lortholary O., et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis: 2008; 46 2 e12 e18
28. Wang L. R., Barber C. E., Johnson A. S., Barnabe C. Invasive fungal disease in systemic lupus erythematosus: a systematic review of disease characteristics, risk factors, and prognosis. Semin Arthritis Rheum: 2014; 44 3 325 330
29. González L. A., Vásquez G., Restrepo J. P., Velásquez M., Ramírez L. A. Cryptococcosis in systemic lupus erythematosus: a series of six cases. Lupus: 2010; 19 5 639 645
30. Bernard C., Maucort-Boulch D., Varron L., et al. French Cryptococcosis Study Group. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. QJM: 2013; 106 6 523 539
31. Yanagawa N., Sakai F., Takemura T., et al. Pulmonary cryptococcosis in rheumatoid arthritis (RA) patients: comparison of imaging characteristics among RA, acquired immunodeficiency syndrome, and immunocompetent patients. Eur J Radiol: 2013; 82 11 2035 2042
32. Chen S. C., Slavin M. A., Heath C. H., et al. Australia and New Zealand Mycoses Interest Group (ANZMIG)-Cryptococcus Study. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis: 2012; 55 6 789 798
33. Zonios D. I., Falloon J., Huang C. Y., Chaitt D., Bennett J. E. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore): 2007; 86 2 78 92
34. Baddley J. W., Schain D. C., Gupte A. A., et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis: 2011; 52 4 e94 e98
35. Sun H. Y., Alexander B. D., Lortholary O., et al. Cryptococcal Collaborative Transplant Study Group. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis: 2010; 51 9 1062 1069
36. Dromer F., Mathoulin S., Dupont B., Laporte A.; French Cryptococcosis Study Group. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). Clin Infect Dis: 1996; 23 1 82 90
37. Kohno S., Kakeya H., Izumikawa K., et al. Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. J Infect Chemother: 2015; 21 1 23 30
38. Hajjeh R. A., Conn L. A., Stephens D. S., et al. Cryptococcal Active Surveillance Group. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis: 1999; 179 2 449 454
39. Lizarazo J., Escandón P., Agudelo C. I., Castañeda E. Cryptococcosis in Colombian children and literature review. Mem Inst Oswaldo Cruz: 2014; 109 6 797 804
40. Chai H. C., Tay S. T. Detection of IgM and IgG antibodies to Cryptococcus neoformans proteins in blood donors and HIV patients with active cryptococcosis. Mycoses: 2009; 52 2 166 170
41. Goldman D. L., Khine H., Abadi J., et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics: 2001; 107 5 E66
42. Goldman D. L., Lee S. C., Mednick A. J., Montella L., Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun: 2000; 68 2 832 838
43. Rodrigues M. L., Casadevall A., Zaragoza O. The architecture and antigenic composition of the polysaccharide capsule. In: Heitman J., Kozel T. R., Kwon-Chung K. J., Perfect J. R., Casadevall A., eds. Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC ASM Press: 2011; 43 54
44. Rodrigues M. L., Alviano C. S., Travassos L. R. Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms. Microbes Infect: 1999; 1 4 293 301
45. Jacobson E. S., Ikeda R. Effect of melanization upon porosity of the cryptococcal cell wall. Med Mycol: 2005; 43 4 327 333
46. Santangelo R., Zoellner H., Sorrell T., et al. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun: 2004; 72 4 2229 2239
47. Wiesner D. L., Moskalenko O., Corcoran J. M., et al. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio: 2012; 3 5
48. Alanio A., Desnos-Ollivier M., Dromer F. Dynamics of Cryptococcus neoformans -macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans. MBio: 2011; 2 4
49. Tseng H. K., Liu C. P., Ho M. W., et al. Taiwan Infectious Diseases Study Network for Cryptococcosis. Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010. PLoS ONE: 2013; 8 4 e61921
50. Chen S., Sorrell T., Nimmo G., et al. Australasian Cryptococcal Study Group. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis: 2000; 31 2 499 508
51. Chen S. C., Korman T. M., Slavin M. A., et al. Australia and New Zealand Mycoses Interest Group (ANZMIG) Cryptococcus Study. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis: 2013; 57 4 543 551
52. Ngamskulrungroj P., Chang Y., Sionov E., Kwon-Chung K. J. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. MBio: 2012; 3 3
53. Okubo Y., Wakayama M., Ohno H., et al. Histopathological study of murine pulmonary cryptococcosis induced by Cryptococcus gattii and Cryptococcus neoformans. Jpn J Infect Dis: 2013; 66 3 216 221
54. Chang C. C., Crane M., Zhou J., et al. HIV and co-infections. Immunol Rev: 2013; 254 1 114 142
55. Hole C. R., Wormley F. L. Jr. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol: 2012; 3 291
56. Antachopoulos C., Walsh T. J. Immunotherapy of Cryptococcus infections. Clin Microbiol Infect: 2012; 18 2 126 133
57. Visnegarwala F., Graviss E. A., Lacke C. E., et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis: 1998; 27 5 1231 1237
58. Zhang Y., Li N., Zhang Y., et al. Clinical analysis of 76 patients pathologically diagnosed with pulmonary cryptococcosis. Eur Respir J: 2012; 40 5 1191 1200
59. Ye F., Xie J. X., Zeng Q. S., Chen G. Q., Zhong S. Q., Zhong N. S. Retrospective analysis of 76 immunocompetent patients with primary pulmonary cryptococcosis. Lung: 2012; 190 3 339 346
60. Song K. D., Lee K. S., Chung M. P., et al. Pulmonary cryptococcosis: imaging findings in 23 non-AIDS patients. Korean J Radiol: 2010; 11 4 407 416
61. Franco-Paredes C., Womack T., Bohlmeyer T., et al. Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis: 2015; 15 3 348 355
62. Kishi K., Homma S., Kurosaki A., Kohno T., Motoi N., Yoshimura K. Clinical features and high-resolution CT findings of pulmonary cryptococcosis in non-AIDS patients. Respir Med: 2006; 100 5 807 812
63. Jenney A., Pandithage K., Fisher D. A., Currie B. J. Cryptococcus infection in tropical Australia. J Clin Microbiol: 2004; 42 8 3865 3868
64. Garrett L., Marr K., West S., Allada G. 74-year-old man from the pacific northwest with fever and a lung mass. Chest: 2011; 140 3 814 817
65. Mitchell D. H., Sorrell T. C. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis: 1992; 14 5 1142 1144
66. Kabanda T., Siedner M. J., Klausner J. D., Muzoora C., Boulware D. R. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis: 2014; 58 1 113 116
67. Rajasingham R., Rolfes M. A., Birkenkamp K. E., Meya D. B., Boulware D. R. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med: 2012; 9 9 e1001316
68. Mahabeer Y., Chang C. C., Naidu D., et al. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans. Diagn Microbiol Infect Dis: 2014; 80 4 294 298
69. Andrade-Silva L., Ferreira-Paim K., Mora D. J., et al. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil. Med Mycol: 2013; 51 6 635 640
70. Bejar V., Tello M., García R., et al. Molecular characterization and antifungal susceptibility of Cryptococcus neoformans strains collected from a single institution in Lima, Peru. Rev Iberoam Micol: 2015; 32 2 88 92
71. Pfaller M. A., Messer S. A., Woosley L. N., Jones R. N., Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol: 2013; 51 8 2571 2581
72. Chang C. C., Ananda-Rajah M., Belcastro A., et al. Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Intern Med J: 2014; 44 (12b): 1389 1397
73. Espinel-Ingroff A., Aller A. I., Canton E., et al. Cryptococcus neoformans - Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother: 2012; 56 11 5898 5906
74. Rapid advice: Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. WHO Library Cataloguing-in-Publication Data,: 2011;. Available at http://www.who.int/hiv/pub/cryptococcal-disease2011/en/
75. Chen S. C., Sorrell T. C., Chang C. C., Paige E. K., Bryant P. A., Slavin M. A. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J: 2014; 44 (12b): 1315 1332
76. Perfect J. R., Dismukes W. E., Dromer F., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis: 2010; 50 3 291 322
77. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2013; Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult-oi.pdf. Accessed October 31, 2011
78. Singh N., Huprikar S., Burdette S. D., Morris M. I., Blair J. E., Wheat L. J.; American Society of Transplantation, Infectious Diseases Community of Practice, Donor-Derived Fungal Infection Working Group. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant: 2012; 12 9 2414 2428
79. Day J. N., Chau T. T., Wolbers M., et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med: 2013; 368 14 1291 1302
80. Flores V. G., Tovar R. M., Zaldivar P. G., Martinez E. A. Meningitis due to Cryptococcus neoformans: treatment with posaconazole. Curr HIV Res: 2012; 10 7 620 623
81. Gamaletsou M. N., Sipsas N. V., Kontoyiannis D. P., et al. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ Diagn Microbiol Infect Dis: 2012; 74 4 409 411
82. Pappas P. G., Bustamante B., Ticona E., et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis: 2004; 189 12 2185 2191
83. Jarvis J. N., Meintjes G., Rebe K., et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS: 2012; 26 9 1105 1113
84. Longley N., Muzoora C., Taseera K., et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis: 2008; 47 12 1556 1561
85. Loyse A., Wilson D., Meintjes G., et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis: 2012; 54 1 121 128
86. Makadzange A. T., Ndhlovu C. E., Takarinda K., et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis: 2010; 50 11 1532 1538
87. Bisson G. P., Molefi M., Bellamy S., et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis: 2013; 56 8 1165 1173
88. Boulware D. R., Meya D. B., Muzoora C., et al. COAT Trial Team. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med: 2014; 370 26 2487 2498
89. Günthard H. F., Aberg J. A., Eron J. J., et al. International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA: 2014; 312 4 410 425
90. Patel D., Desai G. M., Frases S., et al. Methamphetamine enhances Cryptococcus neoformans pulmonary infection and dissemination to the brain. MBio: 2013; 4 4
91. Cahuayme-Zuniga L., Kontoyiannis D. P. Is it safe to proceed with stem cell transplant in cancer patients treated for cryptococcal infection? A focus on recent IDSA cryptococcal guidelines. Clin Infect Dis: 2010; 50 12 1687 1689
92. Powderly W. G., Finkelstein D., Feinberg J., et al. NIAID AIDS Clinical Trials Group. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med: 1995; 332 11 700 705
93. Parkes-Ratanshi R., Wakeham K., Levin J., et al. Cryptococcal Trial Team. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis: 2011; 11 12 933 941
94. McKinsey D. S., Wheat L. J., Cloud G. A., et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis: 1999; 28 5 1049 1056
95. Sun H. Y., Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis: 2011; 53 2 168 176
96. Singh N., Perfect J. R. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis: 2007; 7 6 395 401
97. French M. A., Price P., Stone S. F. Immune restoration disease after antiretroviral therapy. AIDS: 2004; 18 12 1615 1627
98. French M. A. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis: 2009; 48 1 101 107
99. French M. A. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. Med J Aust: 2012; 196 5 318 321
100. Haddow L. J., Colebunders R., Meintjes G., et al. International Network for the Study of HIV-associated IRIS (INSHI). Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis: 2010; 10 11 791 802
101. Chang C. C., Sheikh V., Sereti I., French M. A. Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment. Curr HIV/AIDS Rep: 2014; 11 3 223 232
102. Limper A. H., Knox K. S., Sarosi G. A., et al. American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med: 2011; 183 1 96 128
103. Kaplan J. E., Benson C., Holmes K. K., Brooks J. T., Pau A., Masur H.; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep: 2009; 58 (RR-4): 1 207, quiz CE1-CE4